Pristane-induced plasmacytoma tumor model: time course
Summary:
Analysis of mesentery from BALB/c, DBA, and BALB/DBA animals up to 18 days after intraperitoneal injection of pristane (TMPD). TMPD induces B-cell plasmacytoma (PCT) in 60% of BALB/c animals, but DBA animals remain tumor-free. Results provide insight into the molecular basis of PCT susceptibility.
Zhang K, Kagan D, DuBois W, Robinson R et al. Mndal, a new interferon-inducible family member, is highly polymorphic, suppresses cell growth, and may modify plasmacytoma susceptibility. Blood 2009 Oct 1;114(14):2952-60. PMID: 19654412
